Specific Killing of Ph+Chronic Myeloid Leukemia Cells by a Lentiviral Vector-Delivered Anti-bcr/ablSmall Hairpin RNA
- 1 October 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Oligonucleotides
- Vol. 13 (5) , 401-409
- https://doi.org/10.1089/154545703322617087
Abstract
Chronic myeloid leukemia (CML) is characterized by a reciprocal chromosomal translocation between chromosomes 9 and 22 t(9;22)(q34;q11) that causes fusion of the bcr and abl genes. Transcription and splicing of the fusion gene generate two major splice variants of the bcr/abl transcript that encode an oncoprotein with tyrosine kinase activity. We have taken advantage of lentiviral vectormediated delivery of anti-bcr/abl short hairpin RNAs (shRNA) to downregulate the bcr/abl transcript in Philadelphia chromosome-positive (Ph+) K562 leukemia cells. This downregulation caused complete inhibition of proliferation of these cells and was accompanied by >90% inhibition of the bcr/abl transcript and p210 protein. These results demonstrate the feasibility of using a lentiviral vector to stably transduce therapeutic shRNAs into leukemia cells for the potential ex vivo purging of Ph+ cells in an autologous hematopoietic cell transplant setting. Furthermore, the robust expression of the shRNAs from our lentiviral vector suggests that this system could be generally useful for the expression of other shRNAs.Keywords
This publication has 53 references indexed in Scilit:
- Refractory chronic GVHD emerging after splenectomy in a marrow transplant recipient with accelerated phase CMLBone Marrow Transplantation, 2003
- Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemiaBone Marrow Transplantation, 2003
- Gleevec™ for the Treatment of Chronic Myelogenous Leukemia: U.S. Food and Drug Administration Regulatory Mechanisms, Accelerated Approval, and Orphan Drug StatusThe Oncologist, 2002
- Design of HIV Vectors for Efficient Gene Delivery into Human Hematopoietic CellsMolecular Therapy, 2002
- Purging of chronic myelogenous leukemia cells by retrovirally expressed anti–bcr-abl ribozymes with specific cellular compartmentalizationCancer Gene Therapy, 2002
- Effect of Antisense Oligonucleotides on CD34+ Cells from Chronic Myeloid LeukemiaLeukemia & Lymphoma, 2000
- Treatment of Philadelphia‐chromosome‐positive human leukemia in scid mouse model with herbimycin A, bcr‐abl tyrosine kinase activity inhibitorInternational Journal of Cancer, 1995
- Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reactionThe Lancet, 1991
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990
- Chromosomes and causation of human cancer and leukemia: XL. The Ph1 and other translocations in CMLCancer, 1980